Compare Lowe`s Companies Inc (LOW) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs McKesson Corporation — how do they compare? Lowe`s Companies Inc trades at $186.7 (market cap $105.96B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: Lowe`s Companies Inc and McKesson Corporation are close in size by market cap, and Lowe`s Companies Inc pays the higher dividend (2.65%). Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and McKesson Corporation for 74 Days on average.
| LOW | MCK | |
|---|---|---|
Market Cap | $105.96B | $108.46B |
Volume | 4,039,547 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $995.69 |
52-Week Low | $179.50 | $725.17 |
Typical Hold Time | 98 Days | 74 Days |
Enterprise Value | $144.81B | $115.00B |
Dividend Yield | 2.65% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $186.00, up 2.46% with recent earnings beats but faces bearish technical signals. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector faces macroeconomic headwinds.
Wall Street maintains a bullish consensus with a $244.09 price target (31 Buy, 19 Hold, 1 Sell), representing 31% upside potential. Key risks include housing market stagnation and competitive pressure from Home Depot. The negative shareholder equity position requires monitoring, but consistent dividend payments and operational cash flow strength provide stability.
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
